Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis

BACKGROUND: Hand dexterity impairment is a key feature of disability in people with primary progressive multiple sclerosis (PPMS). So far, ocrelizumab, a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, is the only therapy approved for PPMS and recent anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubbioso, Raffaele, Bove, Marco, Boccia, Daniele, D’Ambrosio, Vincenzo, Nolano, Maria, Manganelli, Fiore, Iodice, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363320/
https://www.ncbi.nlm.nih.gov/pubmed/35419681
http://dx.doi.org/10.1007/s00415-022-11114-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363320/
https://www.ncbi.nlm.nih.gov/pubmed/35419681
http://dx.doi.org/10.1007/s00415-022-11114-x

Ejemplares similares